Company: HCTI
Filing Date: 2025-11-25
Form Type: 424B3
Source: 0001213900-25-114840
Chunk: 24

Company: Healthcare Triangle, Inc.
Filing Date: 2025-11-25
Form: 424B3
Chunk 24
---
arrants following such Fundamental Transaction. In addition, the successor
entity, at the request of holders of Inducement Warrants, will be obligated to purchase any unexercised portion of the Inducement Warrants
in accordance with the terms thereof.

Except as otherwise provided in the Inducement
Warrants or by virtue of such holder’s ownership of shares of Common Stock, the holder of the Inducement Warrants will not have
the rights or privileges of a holder of Common Stock, including any voting rights, until the holder exercises such warrant.

<div align='center'>13

USE OF PROCEEDS</div>

The Selling Stockholders will receive all of the
proceeds of the sale of shares of Common Stock offered from time to time pursuant to this prospectus. Accordingly, we will not receive
any proceeds from the sale of shares of Common Stock that may be sold from time to time pursuant to this prospectus; however, we will
receive proceeds from the cash exercise of the Common Warrants. We currently intend to use these net proceeds for general corporate purposes,
which may include working capital, and general capital expenditures. We have not determined the amount of net proceeds to be used specifically
for any of such purposes.

The expected use of net proceeds from the cash
exercise of the Common Warrants represents our intentions based upon our current plans and business conditions, which could change in
the future as our plans and business conditions evolve and change. The amounts and timing of our actual expenditures, specifically with
respect to working capital, may vary significantly depending on numerous factors. As a result, our management will retain broad discretion
over the allocation of the net proceeds from this offering.

We will bear the out-of-pocket costs, expenses
and fees incurred in connection with the registration of shares of our Common Stock to be sold by the Selling Stockholders pursuant to
this prospectus. Other than registration expenses, the Selling Stockholders will bear any underwriting discounts, commissions, placement
agent fees or other similar expenses payable with respect to sales of shares of our Common Stock.

<div align='center'>14

SELLING STOCKHOLDERS</div>

The shares of Common Stock being offered by the
Selling Stockholders are those issuable to the Inducement Warrant Holders and those issuable to designees of WallachBeth upon exercise
of the Inducement Advisor Warrants. For additional information regarding the issuances of the Common Warrants, see “Warrant Inducement Private Placement”